• Catalog#: C-1016
  
• Targets: BTK
• Synonym: ACP-196, ACP196, ACP 196, Acalabrutinib

Technical Data

• Product Name: ACP-196
• Chemical Formula: n/a
• Moleculer Weight: 244.29
• CAS#: 1420477-60-6
• Appearance: Solid powder
• Purity: > 99% by HPLC
• Solubility: Soluble in DMSO
• Storage: Room temperature for months, or -20ºC for 3 years

Description

ACP-196 (Acalabrutinib) is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, leading to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies. It plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.